<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
AMENDMENT NO. 1
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13D-1(A) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13D-2(A)
MEDICAL TECHNOLOGY SYSTEMS, INC.
--------------------------------
(Name of Issuer)
COMMON STOCK PAR VALUE $.01
---------------------------
(Title of Class of Securities)
58462R505
-----------
(CUSIP Number)
Richard M. Lilly
2424 North Federal Highway, Suite 311
Boca Raton, Florida 33421
(561) 391-4222
-----------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
SEPTEMBER 26, 2000
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
<PAGE> 2
SCHEDULE 13D
Amendment No. 1
CUSIP NO. 58462R505 PAGE 2 OF 6 PAGES
--------------------- -------- --------
(1) NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
RICHARD M. LILLY
###-##-####
---------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
---------------------------------------------------------------------
(3) SEC USE ONLY
---------------------------------------------------------------------
(4) SOURCE OF FUNDS*
PF
---------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS [ ]
IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
---------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
---------------------------------------------------------------------
(7) SOLE VOTING POWER
NUMBER OF 412,725 shares of common stock
SHARES --------------------------------------------------------
BENEFICIALLY (8) SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------
REPORTING (9) SOLE DISPOSITIVE POWER
PERSON WITH 412,725 shares of common stock
--------------------------------------------------------
(10) SHARED DISPOSITIVE POWER
0
--------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,725 shares of common stock
---------------------------------------------------------------------
(12) CHECK BOX IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
---------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Approximately 6.31% of the issued and outstanding common stock.
---------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
---------------------------------------------------------------------
<PAGE> 3
ATTACHMENT
ITEM 1. SECURITY AND ISSUER
Common stock, par value $.01.
Medical Technology Systems, Inc.
12920 Automobile Boulevard
Clearwater, Florida 33762
ITEM 2. IDENTITY AND BACKGROUND
(a) Name: Richard M. Lilly (Richard M. Lilly Revocable Trust)
(b) Business Address: 2424 North Federal Highway, Suite 311
Boca Raton, Florida 33431
(c) Principal Occupation:
Mr. Lilly is an investment banker with Indianapolis Securities, Inc., a
registered broker-dealer whose office is set forth in (b) above.
(d) Mr. Lilly, during the last five years, has not been convicted in a
criminal proceeding.
(e) Mr. Lilly, during the last five years, was not a party to a civil
proceeding of a judicial or administrative body of competent
jurisdiction which as a result of such proceeding was subject to a
judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws.
(f) Citizenship: United States
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Personal funds in the aggregate amount of $50,338.15 were used to make the
purchases of shares of common stock of the Company described in Item 5(c).
Personal funds in the aggregate amount of $201,634.56 were used to acquire the
aggregate amount of 412,725 shares of common stock of the Company presently
owned by the Reporting Person.
<PAGE> 4
ITEM 4. PURPOSE OF THE TRANSACTION
Mr. Lilly has obtained his shares principally for investment purposes. However,
he will continue to evaluate the Company and its current management and reserve
options as to any future actions he may take. He has preliminarily reviewed the
proposed recapitalization plan announced on July 31, 2000 and does not believe
such plan is in the best interest of the Company or its shareholders. However,
Mr. Lilly does not presently intend to solicit proxies for opposition to such
plan at its scheduled annual meeting.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) 412,725 shares of common stock, constituting approximately 6.31% of the
issued and outstanding common stock.
(b) There is sole power to vote or to direct the vote and sole power to
dispose or to direct the disposition of the 412,725 shares of common
stock held by the Reporting Person.
(c) Set forth below is a list of the transactions of the Reporting Person
since the Reporting Person's last filing of Schedule 13D. The
transactions were brokerage transactions.
<TABLE>
<CAPTION>
Trade Date Settlement Date Quantity Price Net Amount
--------------- --------------- -------- ------ ----------
<S> <C> <C> <C> <C>
August 15, 2000 August 18, 2000 3,000 0.6618 1,985.26
August 16, 2000 August 21, 2000 20,000 0.6930 13,859.00
August 16, 2000 August 21, 2000 16,700 0.6605 11,030.68
August 16, 2000 August 21, 2000 1,000 0.6603 660.25
August 18, 2000 August 23, 2000 200 0.6828 136.55
August 23, 2000 August 28, 2000 225 0.6490 146.03
September 22, 2000 September 27, 2000 5,000 0.6299 3,149.50
September 22, 2000 September 27, 2000 5,500 0.6621 3,641.38
September 26, 2000 September 29, 2000 10,000 0.6295 6,294.50
September 26, 2000 September 29, 2000 15,000 0.6290 9,435.00
</TABLE>
(d) No other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of
such securities.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
None.
2
<PAGE> 5
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
None.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this Amendment No. 1 to the Statement on
Schedule 13D is true, complete and correct as of the date hereof.
Dated: October 26, 2000
/s/ Richard M. Lilly
-------------------------------
Richard M. Lilly
3
